Inhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?
Monaldi Archives for Chest Disease · 2025
DOI: 10.4081/monaldi.2025.3129 ↗Kurz gefasst
Fachartikel in der Zeitschrift Monaldi Archives for Chest Disease, 2025. Verfasst von Srishankar Bairy und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Father Muller Medical College, Mangaluru, Karnataka. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Asthma, Adrenal Cortex Hormones, Beclomethasone. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: COPD
Abstract (Originalsprache)
The term "asthma-chronic obstructive pulmonary disease (COPD) combined phenotype” describes patients with persistent airflow limitation and features of both asthma and COPD. There is a lack of data on effective treatments for this group, often excluded from asthma or COPD trials. Inhaled corticosteroids (ICS) are standard for asthma, while bronchodilators are key for COPD. This study is a prospective interventional study that included 43 patients diagnosed with the asthma-COPD overlap phenotype, as per Sin et al. criteria, who were treated as COPD priorly and followed over one year. These patients received additional treatment with a moderate-dose ICS metered dose inhaler beclamethasone 800 mcg daily, in addition to their optimal inhaled bronchodilator therapy. Follow-up spirometry along with reversibility, fractional exhaled nitric oxide (FeNO), blood investigations like total eosinophil count (TEC) and immunoglobulin E (IgE) were done; sputum eosinophils were measured, and a history of exacerbations was noted. These parameters were compared with baseline values obtained prior to the initiation of ICS to evaluate the impact of the intervention. Among the 43 individuals in the study population, the majority fell within the age group of 60-69 years. The addition of ICS to bronchodilators over a one-year period resulted in significant improvements in their forced expiratory volume in one second. Additionally, there was a notable reduction in the FeNO level, along with decreases in the TEC, serum IgE levels, and sputum eosinophils. Although the number of exacerbations decreased during the study period in this subgroup, this reduction did not reach statistical significance. Based on these findings, the study suggests that ICS should be considered as an adjunct to inhaled bronchodilators for the management of stable COPD patients exhibiting features of the asthma-COPD combined phenotype.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory Medicine, Father Muller Medical College, Mangaluru, Karnataka.
- Government Medical College, Dhaulpur, Rajasthan.
- District Tuberculosis Center, Tonk, Rajasthan.
- Department of Respiratory Medicine, JLN Medical College, Ajmer, Rajasthan.
- Department of Community Medicine, K.S. Hegde Medical College, Deralakatte, Karnataka.
ORCID-Profile: Srishankar Bairy, Tarun Tiwari, Himanshu Mittal, Neeraj Gupta, Meghana M
Zitieren
APA
Bairy, S., Tiwari, T., Mittal, H., Gupta, N., & M, M. (2025). Inhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?. Monaldi Archives for Chest Disease. https://doi.org/10.4081/monaldi.2025.3129
Vancouver
Bairy S, Tiwari T, Mittal H, Gupta N, M M. Inhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?. Monaldi Archives for Chest Disease. 2025. doi:10.4081/monaldi.2025.3129
BibTeX
@article{Bairy2025,
author = {Bairy, Srishankar and Tiwari, Tarun and Mittal, Himanshu and Gupta, Neeraj and M, Meghana},
title = {Inhaled corticosteroids in asthma and chronic obstructive pulmonary disease combined phenotype: when to use and what to expect?},
journal = {Monaldi Archives for Chest Disease},
year = {2025},
doi = {10.4081/monaldi.2025.3129}
}
EUVIMED